Additional file 1: Supplementary Table 1. The low-purine diet. Supplementary Table 2. Adverse events during the study. Supplementary Table 3. Baseline clinical variables associated with the SU target achievement
Richard Sheer,1 Kyle D Null,2 Keith A Szymanski,2 Lavanya Sudharshan,1 Jennifer Banovic,2 Margaret K...
The methodological quality of cross-sectional studies in accordance with the Newcastle-Ottawa Scale ...
Association between serum urate levels (ÎźmolL â1) and consumption of five established urate influ...
Table S1. Summary of medical histories of patients with nonfatal serious TEAEs. (DOCX 21Â kb
Table S6. Unadjusted univariate association between prevalent gout and clinical covariates assessed ...
Table S1. Type and dosage of diuretics. Table S2. Comparison of maximum dose of urate-lowering drugs...
Table S1. Prevalence of gout by age group and gender from the South Australian 2015 Health Omnibus S...
Figure S1. Landmark analysis. (A) 1-year landmark. (B) 3-year landmark. (TIF 1482 kb
Is a table presenting additional information on the variables included in the propensity score model...
Figure S1. Box plot of the initial volume of monosodium urate deposits in the feet measured with dua...
Table S1. Renal-related and kidney stone TEAEs. Table S2. TEAEs with >â5% of patients in either to...
Table S2. Demographic characteristics and prevalence (95% CIs) of comorbidities for gout cases and c...
Figure S3. Estimated risk of incident gout by serum urate only. Serum urate was entered either linea...
Figure S5. Estimated risk of prevalent gout versus serum urate by risk groups. (PNG 263 kb
Objective: To assess the effect of treatment with febuxostat versus placebo on joint damage in hyper...
Richard Sheer,1 Kyle D Null,2 Keith A Szymanski,2 Lavanya Sudharshan,1 Jennifer Banovic,2 Margaret K...
The methodological quality of cross-sectional studies in accordance with the Newcastle-Ottawa Scale ...
Association between serum urate levels (ÎźmolL â1) and consumption of five established urate influ...
Table S1. Summary of medical histories of patients with nonfatal serious TEAEs. (DOCX 21Â kb
Table S6. Unadjusted univariate association between prevalent gout and clinical covariates assessed ...
Table S1. Type and dosage of diuretics. Table S2. Comparison of maximum dose of urate-lowering drugs...
Table S1. Prevalence of gout by age group and gender from the South Australian 2015 Health Omnibus S...
Figure S1. Landmark analysis. (A) 1-year landmark. (B) 3-year landmark. (TIF 1482 kb
Is a table presenting additional information on the variables included in the propensity score model...
Figure S1. Box plot of the initial volume of monosodium urate deposits in the feet measured with dua...
Table S1. Renal-related and kidney stone TEAEs. Table S2. TEAEs with >â5% of patients in either to...
Table S2. Demographic characteristics and prevalence (95% CIs) of comorbidities for gout cases and c...
Figure S3. Estimated risk of incident gout by serum urate only. Serum urate was entered either linea...
Figure S5. Estimated risk of prevalent gout versus serum urate by risk groups. (PNG 263 kb
Objective: To assess the effect of treatment with febuxostat versus placebo on joint damage in hyper...
Richard Sheer,1 Kyle D Null,2 Keith A Szymanski,2 Lavanya Sudharshan,1 Jennifer Banovic,2 Margaret K...
The methodological quality of cross-sectional studies in accordance with the Newcastle-Ottawa Scale ...
Association between serum urate levels (ÎźmolL â1) and consumption of five established urate influ...